CSRXP APPLAUDS POSITIVE PROGRESS, ENCOURAGES POLICYMAKERS TO ADVANCE ADDITIONAL MARKET-BASED SOLUTIONS TO HOLD BIG PHARMA ACCOUNTABLE

02-8-2023 Press Release

Policies Must Address Big Pharma’s Egregious Practices That Cause High Drug Prices Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released the following statement Tuesday on President Biden’s remarks on prescription drug prices during the State of the Union address. “CSRxP applauds the positive progress made by President Biden and lawmakers in the last […]

CSRXP APPLAUDS USPTO EFFORTS TO CRACK DOWN ON BIG PHARMA’S PATENT ABUSE AND SUPPORTS ADDITIONAL SOLUTIONS TO BOOST COMPETITION TO HELP LOWER DRUG PRICES

02-1-2023 Press Release

Comment Letters Highlight Key Agency Initiatives Targeting Brand Name Drug Companies’ Anti-Competitive Tactics, Outline Areas for Further Action and Collaboration Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) submitted two letters to the United States Patent and Trademark Office (USPTO) this week in response to requests for comment on efforts the agency can take […]

CSRXP POLL: VOTERS OVERWHELMINGLY SUPPORT HOLDING BIG PHARMA ACCOUNTABLE TO BUILD ON POSITIVE PROGRESS TOWARD LOWERING RX PRICES

01-24-2023 Press Release

Broad Majorities Reject Big Pharma’s Blame Game and Want Policymakers to Advance Market-Based Solutions to Crack Down on Big Pharma’s Egregious Pricing and Anti-Competitive Practices Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released the results of a national survey conducted by Morning Consult today that found American voters overwhelmingly reject Big Pharma’s blame […]

CSRXP: BIG PHARMA DOUBLES DOWN ON BUSINESS-AS-USUAL AS JANUARY PRICE HIKES CLIMB TO 587

01-19-2023 Press Release

Brand Name Drug Companies Increase Prices on Treatments for Serious Conditions Like Cancers, Autoimmune Conditions, Seizures and More Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Thursday reacting to brand name drug companies hiking prices on 587 brand name drugs over the first two weeks of 2023 by an average of 5.5 percent. “Big […]

CSRXP: MODERNA’S 500 PERCENT VACCINE PRICE HIKE A BRAZEN DEMONSTRATION OF BIG PHARMA’S GREED

01-9-2023 Press Release

Brand Name Drug Companies Continue Seeking to Price-Gouge COVID-19 Treatments and Vaccines Ahead of Transition to Commercial Market Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Monday in response to reports that Moderna plans to hike the price of the company’s COVID-19 vaccine from $26.36 to as much as $130 per dose as payment […]

CSRXP: BIG PHARMA WELCOMES NEW YEAR BY HIKING PRICES ON HUNDREDS OF PRESCRIPTION DRUGS

01-3-2023 Press Release

Brand Name Drug Companies Maintain Business-as-Usual Approach to Price-Gouging the American People at the Start of 2023 Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today in response to reports brand name drug companies will hike prices on at least 350 prescription drugs to start the new year, part of a pharmaceutical industry […]

CSRXP: NEW MOST EXPENSIVE DRUG IN THE WORLD CARRIES PRICE TAG $600,000 HIGHER THAN ESTIMATES FOR A FAIR PRICE

11-30-2022 Press Release

Hemgenix Pricing Reflects Escalating Big Pharma Trend of Setting Higher and More Out-of-Control Launch Prices on New Products Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today in response to pharmaceutical companies CSL Behring and uniQure setting a $3.5 million price tag on their hemophilia drug Hemgenix, which was recently approved […]

CSRXP: OUTRAGEOUS PRICE TAG ON NEW DIABETES DRUG LATEST EXAMPLE OF BIG PHARMA’S OUT-OF-CONTROL LAUNCH PRICES

11-21-2022 Press Release

Drug Company Sets Nearly $200,000 Price on Newly Approved Treatment for Type 1 Diabetes, Blowing Past Wall Street Expectations Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today in response to Provention Bio setting a $193,900 price tag for a course of treatment with the brand name prescription drug Tzield, which […]

CSRXP APPLAUDS FDA APPROVAL OF SECOND INTERCHANGEABLE BIOSIMILAR FOR INSULIN

11-18-2022 Press Release

Interchangeable Biosimilars Help Provide Patients with Greater Choice and More Affordable Alternatives to High-Priced Brand Name Drugs Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today in response to the Food and Drug Administration’s (FDA) decision to approve interchangeable biologic drug Rezvoglar, as a second alternative to brand name drug manufacturer […]

CSRXP: PFIZER’S EGREGIOUS VACCINE PRICE HIKE DEMONSTRATES URGENCY TO BUILD ON POSITIVE PROGRESS TO HOLD BIG PHARMA ACCOUNTABLE

10-21-2022 Press Release

Big Pharma Companies Want to Price-Gouge the American People and Health Care System as COVID-19 Vaccine and Therapeutic Coverage Shifts to Commercial Market Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Friday in response to reports that brand name pharmaceutical giant Pfizer is planning to hike the price of the company’s COVID-19 vaccine as payment […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.